A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

Incidence and severity of adverse events (AEs)

Number of subjects who experienced adverse events and severity of adverse events

Time frame: Through study completion upto 6weeks depending on cohorts

Incidence and severity of adverse events of special interest (AESIs) in Part 2 (MAD)

Number of subjects who experienced adverse events of special interest (AESIs)

Time frame: Through study completion upto 6weeks depending on cohorts

Change from baseline in vital signs (blood pressure)

Absolute values and changes from baseline (BP assessed by 24-hour ambulatory blood pressure monitoring (ABPM);systolic pressure and diastolic pressure will be assessed

Time frame: Through study completion upto 6weeks depending on cohorts

Change from baseline in vital signs (heart rate)

Absolute values and changes from baseline (HR assessed by 24-hour ambulatory electrocardiography monitoring (12-lead cardiac telemetry; central reader))

Time frame: Through study completion upto 6weeks depending on cohorts

Change from baseline in vital signs (weight in kilograms, height in meters)

weight and height will be combined to report BMI in kg/m\^2

Time frame: Through study completion upto 6weeks depending on cohorts